Biotechnology
ABVC BioPharma Achieves $150K Milestone in Licensing Strategy, Highlighting Growth in Botanical Therapeutics
ABVC BioPharma's recent $150,000 milestone payment from AiBtl BioPharma underscores the success of its licensing-first strategy and the growing interest in its CNS-focused botanical therapeutics.
Intelligent Bio Solutions Inc. to Showcase Fingerprint Sweat PK Study at ADLM 2025 Clinical Lab Expo
Intelligent Bio Solutions Inc. will present its pharmacokinetic study data at the ADLM 2025 Clinical Lab Expo, highlighting the reliability of fingerprint sweat as a non-invasive diagnostic tool for drug screening.
Calidi Biotherapeutics Inc. Secures $4.6 Million Through Warrant Exercise Agreement
Calidi Biotherapeutics Inc. has raised $4.6 million by exercising outstanding warrants, funding its innovative cancer treatment research and development efforts.
Jupiter Neurosciences Advances in Treating Neuroinflammation and Aging with JOTROL™ and Nugevia™
Jupiter Neurosciences Inc. is making strides in treating central nervous system disorders and tapping into the longevity market with its innovative products JOTROL™ and Nugevia™, highlighting the potential to combat aging and neuroinflammation.
CNS Pharmaceuticals Inc. Showcases Lead Cancer Treatment Program in Virtual CEO Segment
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) emphasizes its lead cancer treatment program during a virtual CEO segment, highlighting potential advancements in brain and central nervous system cancer therapies.
Soligenix Inc. Targets Key Milestones in Rare Disease Pipeline with Potential $2 Billion Global Opportunity
Soligenix Inc. outlines significant clinical and strategic milestones for its rare disease therapies, including Phase 3 FLASH 2 results for HyBryte(TM) and updates on psoriasis and Behçet’s Disease treatments, projecting over $90 million in U.S. annual sales and global opportunities exceeding $2 billion.
Calidi Biotherapeutics Innovates with Genetic Medicines for Cancer Treatment
Calidi Biotherapeutics Inc. is pioneering a next-generation platform to deliver genetic medicines directly to tumors, offering new hope for hard-to-treat cancers and positioning itself among leading biotech innovators.
Calidi Biotherapeutics Inc. Showcases Breakthrough in Cancer Treatment with Genetic Medicine Platform
Calidi Biotherapeutics Inc. (NYSE American: CLDI) is pioneering a precision genetic medicine platform aimed at revolutionizing cancer treatment by targeting both primary and metastatic tumors with engineered viruses.
Fifty 1 Labs and UAV Corp Unveil AI-Driven Strategy for NASDAQ Uplisting
Fifty 1 Labs, Inc. and UAV Corp announce a strategic plan to achieve a $50 million valuation and uplist to NASDAQ, leveraging AI in drug repurposing and functional medicine.
Calidi Biotherapeutics' Genetic Medicine Platform Featured in Editorial for Cancer Treatment Innovation
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been highlighted in an editorial for its precision genetic medicine platform, offering a novel approach to targeting cancer tumors amidst rising global diagnoses.
Calidi Biotherapeutics' Genetic Medicine Platform Highlighted for Potential Cancer Breakthrough
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been featured in an editorial for its precision genetic medicine platform, which could revolutionize cancer treatment by targeting tumors with engineered viruses.
Benova Mouth Rinse Study Shows Significant Reduction in Inflammatory Marker TNF-Alpha
A recent study presented at the 2025 Diabetic Limb Salvage Conference reveals the Benova Mouth Rinse System's ability to reduce TNF-alpha, a key inflammatory marker, by 17% within two minutes, offering potential relief for millions suffering from oral inflammatory conditions.
Clene Inc. Advances Neurofilament Biomarker Analysis for CNM-Au8 in ALS with FDA Support
Clene Inc. is set to conduct a neurofilament biomarker analysis for CNM-Au8 in ALS patients, following constructive FDA feedback, aiming to support an accelerated approval submission in 2025.
Precision Genetic Medicine Platform Offers New Hope in Cancer Treatment
Calidi Biotherapeutics Inc. is pioneering a novel approach to cancer treatment with its precision genetic medicine platform, targeting both primary tumors and metastatic sites, potentially transforming cancer care and addressing other unmet medical needs.
Biotech Sector Rebounds with Innovative Therapies and Strategic Growth in 2025
The biotech sector is witnessing a significant rebound in 2025, driven by scientific advancements, clinical progress, and a favorable investment climate, highlighting four stocks with potential for growth.
GeoVax Advances Mpox Vaccine Development Amid Rising Global Cases
GeoVax Labs accelerates its GEO-MVA vaccine development for Mpox and smallpox, responding to global health threats and regulatory advancements.
MS Tech Secures $1.2M R&D Grant for Early Disease Detection Biosensors
MS Tech Ltd. has been awarded a $1.2M R&D grant by the Israel Innovation Authority to advance its innovative biosensor technology for early disease screening and biomarkers diagnostics, marking a significant step forward in point-of-care diagnostics.
New Study Reveals Pesticides' Impact on Gut Microbes and Inflammation
A preclinical study highlights how pesticide compounds disrupt gut bacteria linked to inflammation, offering potential insights for biotech R&D.
Nutriband Inc. Added to Four Russell Indexes, Highlighting Market Recognition and Growth Potential
Nutriband Inc.'s inclusion in four Russell indexes underscores the market's recognition of its AVERSA pipeline and its potential impact on the pharmaceutical industry.
Oragenics Inc. Announces $20 Million Preferred Stock and Warrant Offering to Fund Concussion Trials and R&D
Oragenics Inc. secures up to $20 million through a preferred stock and warrant offering to advance its ONP-2 concussion trials and support R&D efforts.
GeoVax Announces $6 Million Public Offering to Advance Immunotherapies and Vaccines
GeoVax Labs, Inc. secures approximately $6 million in a public offering to fund the development of its immunotherapies and vaccines against cancer and infectious diseases.
Soligenix Inc. Advances Novel Immunotherapy to Combat Antibiotic Resistance
Soligenix Inc. is developing SGX943, a novel immunotherapy that enhances the body's immune response to combat bacterial infections, addressing the critical challenge of antibiotic resistance.
Stem Cell and Gene Therapy Innovations Poised to Transform Medicine
The stem cell and gene therapy sectors are experiencing rapid growth, with innovations from companies like Adia Nutrition Inc., Mesoblast, Lineage Cell Therapeutics, and CRISPR Therapeutics leading the charge towards transformative treatments for serious diseases.
Siren Biotechnology and RISE Robotics Triumph at Superpowers for Good Live Pitch Q2 2025
Siren Biotechnology and RISE Robotics were recognized for their innovative contributions to cancer treatment and energy-efficient industrial motion systems at the Superpowers for Good Live Pitch, highlighting the event's role in fostering impactful entrepreneurship.
Calidi Biotherapeutics Inc. Advances Oncology Pipeline and Strategic Goals in 2025
Calidi Biotherapeutics Inc. outlines significant progress in its oncology immunotherapy pipeline and strategic initiatives aimed at enhancing shareholder value and advancing cancer treatment options.
SeaStar Medical's QUELIMMUNE Shows Promise in Treating Pediatric AKI
SeaStar Medical's QUELIMMUNE device, approved by the FDA, significantly reduces mortality rates in pediatric patients with acute kidney injury (AKI) by targeting the cytokine storm at its source.
Aditxt Inc. CEO to Showcase Innovation at Wall Street Reporter’s NEXT SUPER STOCK Event
Aditxt Inc.'s CEO Amro Albanna will present the company's health innovation strategies and updates on key programs at the NEXT SUPER STOCK event, highlighting its potential impact on the healthcare sector.
Growing Public Interest in Mitochondrial Function Testing Highlights Advances in Health and Longevity
The increasing public interest in mitochondrial health testing underscores significant advancements in addressing mitochondrial dysfunction and its implications for overall wellness and longevity.
BiomX Inc.: A Biotech Pioneer with Pentagon Backing and Promising Phage Therapy
BiomX Inc. (NYSE: PHGE), a biotech company with a market cap of $13 million, has secured $40 million in non-dilutive funding from the U.S. Defense Health Agency, highlighting its potential in addressing antibiotic-resistant infections with phage therapy.
ABVC BioPharma CEO Recognized Among Influential Indian-Origin CEOs in Global Biotech
Dr. Uttam Patil, CEO of ABVC BioPharma, is highlighted for his leadership in advancing a novel botanical antidepressant, ABV-1504, which could revolutionize treatment for Major Depressive Disorder by eliminating suicidal ideation side effects.